N-(2-naphthalenesulfonyl)-L-valyl-L-leucinal | 190274-46-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: N-(2-naphthalenesulfonyl)-L-valyl-L-leucinal
• 英文别名: (2S)-3-methyl-N-[(2S)-4-methyl-1-oxopentan-2-yl]-2-(naphthalen-2-ylsulfonylamino)butanamide
• CAS: 190274-46-5
• 化学式: C₂₁H₂₈N₂O₄S
• 分子量: 404.53
• InChiKey: VWOMPLBSHLGHCT-ICSRJNTNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  28
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  101
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  N-(2-naphthalenesulfonyl)-L-valine 在 pyridine-SO3 complex 、 二甲基亚砜 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 6.67h， 生成 N-(2-naphthalenesulfonyl)-L-valyl-L-leucinal
  参考文献：
  名称：

  Structure−Activity Relationship Study and Drug Profile of N-(4-Fluorophenylsulfonyl)-l-valyl-l-leucinal (SJA6017) as a Potent Calpain Inhibitor

  摘要：

  Novel N-arylsulfonyldipeptidyl aldehyde derivatives were prepared by DMSO oxidation from the corresponding dipeptide alcohol, and their potencies as calpain inhibitors were evaluated in vitro. Among them, N-(4-fluorophenylsulfonyl)-L-valyl-L-leucinal (8, SJA6017) potently inhibited calpains. 8 also inhibited cathepsin B and L but did not inhibit other cysteine proteases (interleukin 1beta-converting enzyme), serine proteases (trypsin, chymotrypsin, thrombin, factor VIIa, factor Xa), or proteasome. Preliminary cytotoxicity studies of 8 exhibited a relatively safe profile.

  DOI：

  10.1021/jm0201924
• 作为试剂：
  描述：

  N-(2-naphthalenesulfonyl)-L-valyl-L-leucinol 、 三乙胺 、 乙酸乙酯 在 三氧化硫吡啶 、 盐酸 、 碳酸氢钠 、 Brine 、 magnesium sulfate 、 ethyl acetate n-hexane 、 N-(2-naphthalenesulfonyl)-L-valyl-L-leucinal 作用下， 以 二甲基亚砜 、 二氯甲烷 为溶剂， 反应 2.0h， 以to give 0.98 g of N-(2-naphthalenesulfonyl)-L-valyl-L-leucinal (Compound 34) as white crystals的产率得到N-(2-naphthalenesulfonyl)-L-valyl-L-leucinal
  参考文献：
  名称：

  Angiogenesis inhibitor

  摘要：

  一种抑制血管生成的抑制剂，包括半胱氨酸蛋白酶抑制剂化合物。作为首选的半胱氨酸蛋白酶抑制剂化合物，可以使用环氧琥珀酸化合物、肽卤酰肼化合物、钙蛋白酶抑制剂化合物、式（I）化合物和式（VI）化合物。本发明的血管生成抑制剂抑制了活体组织中新的血管形成，因此可用作优良的血管生成相关治疗或预防剂，如伤口愈合、炎症、肿瘤生长等；以及糖尿病视网膜病变、早产儿视网膜病变、视网膜静脉阻塞、老年性圆盘状黄斑变性等所见的血管生成，以及预防肿瘤转移。

  公开号：

  US06214800B1

文献信息

• OPHTHALMIC ADHESIVE PREPARATIONS FOR PERCUTANEOUS ABSORPTION
  申请人：Senju Pharmaceutical Co., Ltd.

  公开号：EP1221315A1

  公开（公告）日：2002-07-10

  Ophthalmic transdermal patches are disclosed for treating diseases of the posterior segment of the eye comprising a drug-containing layer uniformly containing in a base matrix a percutaneous absorption enhancer, which is polyoxyethylene oleyl ether and/or isopropyl myristate, and a drug to be delivered to the posterior segment of the eye including the lens, the vitreous body, the uvea and the retina.

  本发明公开了用于治疗眼球后段疾病的眼科透皮贴片，该贴片包括一个含药层，在基质中均匀地含有一种经皮吸收促进剂，该促进剂是聚氧乙烯油基醚和/或肉豆蔻酸异丙酯，以及一种要输送到眼球后段（包括晶状体、玻璃体、葡萄膜和视网膜）的药物。
• DRUG COMPOSITION COMPRISING DIPEPTYDYL ALDEHYDE DERIVATIVE
  申请人：Senju Pharmaceutical Co., Ltd.

  公开号：EP1334718A1

  公开（公告）日：2003-08-13

  The present invention provides a preparation containing a compound of the formula (I) wherein R1 is an alkyl group having 1 to 4 carbon atoms or an optionally substituted aryl group having 6 to 10 carbon atoms; R2 and R3 are the same or different and each is hydrogen or an alkyl group having 1 to 4 carbon atoms, or R2 and R3 in combination form a ring having 3 to 7 carbon atoms; and R4 is a lower alkyl group optionally substituted by aryl, cycloalkyl or aromatic heterocyclic residue, or a pharmaceutically acceptable salt thereof together with a lipid. The preparation shows improved stability and improved absorption and penetration into tissue.

  本发明提供了一种含有式（I）化合物的制剂 其中 R1 是具有 1 至 4 个碳原子的烷基或具有 6 至 10 个碳原子的任选取代的芳基；R2 和 R3 相同或不同，且各自是氢或具有 1 至 4 个碳原子的烷基，或 R2 和 R3 结合形成具有 3 至 7 个碳原子的环；R4 是任选被芳基、环烷基或芳香杂环残基取代的低级烷基，或其药学上可接受的盐以及脂质。该制剂显示出更高的稳定性，以及更好的吸收性和组织渗透性。
• Pharmaceutical composition for prophylaxis and therapy of diseases associated with ocular fundus tissue cytopathy
  申请人：Senju Pharmaceutical Co., Ltd.

  公开号：EP1504760A1

  公开（公告）日：2005-02-09

  The invention relates to the use of a compound of the fol'lowing formula (I) wherein R1 represents an alkyl group having 1 to 4 carbon atoms or an aryl group having 6 to 10 carbon atoms which is optionally substituted; R2 and R3 may be the same or different and each represents hydrogen or an alkyl group having 1 to 4 carbon atoms or R2 and R3 may jointly form a ring having 3 to 7 carbon atoms; and R4 represents a lower alkyl group which is optionally substituted by aryl, cycloalkyl, or aromatic heterocyclic residue, or a pharmaceutically acceptable salt thereof for the production of a pharmaceutical agent for the prophylaxis or treatment of a disease selected from the group consisting of retinal periphlebitis, Eales' disease, ischemic eye syndrome, retinal arteriolar macroaneurysm, retinopathy associated with hypertension or renal disease, retinal pigment epithelitis, retinal dystrophy, macular dystrophy, retinochoroidal atrophy, retinochoroiditis, macular edema, retinal pigment epithelial detachment, retinal detachment, degenerative retinoschisis, retinoblastoma, tumors of the retinal pigment epithelium, capillary hemangioma of the optic nerve head, ischemic optic neuropathy, and choked disc/papilledema.

  本发明涉及下式（I）化合物的用途 其中 R1 代表具有 1 至 4 个碳原子的烷基或具有 6 至 10 个碳原子并被任选取代的芳基；R2 和 R3 可以相同或不同，且各自代表氢或具有 1 至 4 个碳原子的烷基，或 R2 和 R3 可共同形成一个具有 3 至 7 个碳原子的环；和 R4 代表被芳基、环烷基或芳香杂环残基任选取代的低级烷基，或其药学上可接受的盐，用于生产预防或治疗选自以下组别的疾病的药剂：视网膜静脉周围炎、Eales 病、缺血性眼综合征、视网膜动脉大动脉瘤、与高血压或肾脏疾病相关的视网膜病变、视网膜色素上皮炎、视网膜营养不良、黄斑营养不良、视网膜脉络膜萎缩、视网膜脉络膜炎、黄斑水肿、视网膜色素上皮脱落、视网膜脱离、退行性视网膜裂孔、视网膜母细胞瘤、视网膜色素上皮肿瘤、视神经头毛细血管瘤、缺血性视神经病变和窒息性视盘/视网膜水肿。
• Drug composition comprising dipeptidyl aldehyde derivative
  申请人：——

  公开号：US20040048929A1

  公开（公告）日：2004-03-11

  The present invention provides a preparation containing a compound of the formula (I) 1 wherein R 1 is an alkyl group having 1 to 4 carbon atoms or an optionally substituted aryl group having 6 to 10 carbon atoms; R 2 and R 3 are the same or different and each is hydrogen or an alkyl group having 1 to 4 carbon atoms, or R 2 and R 3 in combination form a ring having 3 to 7 carbon atoms; and R 4 is a lower alkyl group optionally substituted by aryl, cycloalkyl or aromatic heterocyclic residue, or a pharmaceutically acceptable salt thereof together with a lipid. The preparation shows improved stability and improved absorption and penetration into tissue.

  本发明提供了一种含有式（I）化合物的制剂 1 其中 R 1 是具有 1 至 4 个碳原子的烷基或具有 6 至 10 个碳原子的任选取代的芳基；R 2 和 R 3 相同或不同，且各自为氢或具有 1 至 4 个碳原子的烷基，或 R 2 和 R 3 组合形成一个具有 3 至 7 个碳原子的环；以及 R 4 是可选被芳基、环烷基或芳香杂环残基取代的低级烷基，或其与脂质一起组成的药学上可接受的盐。该制剂具有更好的稳定性，更易被组织吸收和渗透。
• PHARMACEUTICAL COMPOSITION FOR PROPHYLAXIS AND THERAPY OF DISEASES ASSOCIATED WITH OCULAR FUNDUS TISSUE CYTOPATHY
  申请人：Senju Pharmaceutical Co., Ltd.

  公开号：EP1058553A2

  公开（公告）日：2000-12-13